A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. 9 Guanghua Road, Chaoyang District, Beijing. Founded in 2020. By using this site, you agree that we may store and access cookies on your device. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Get involved to accelerate your cross-border partnering strategies. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. 700, Boston, MA 02110. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Primary Office 4-B101-125, Creative Industry Park, No. Federal government websites often end in .gov or .mil. . Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Suzhou, Jiangsu The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. AllianThera Biopharma. Show more Frequently Asked Questions At Recludix, we are innovators and inventors. Mol Cancer Ther 2021;20:196676. Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . -. Jobs at AllianThera Biopharma. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Careers. Company. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Description. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. Cancer Lett. CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. N Engl J Med 2018;378:11325. If this sounds like you, please get in touch with us. The .gov means its official. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. Sign in with Apple. Unauthorized use of these marks is strictly prohibited. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). Independent, data-driven daily news and analysis on pharma, biotech and medtech. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Win whats next. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Linkedin Terms were not disclosed. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. This is the AllianThera Biopharma company profile. 12 Dana-Farber Cancer Institute, Boston, United States. Before alicia@thrustsc.com. Advanced Search Title. work@designtx.com. 2023 PitchBook. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. The site is secure. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? Bethesda, MD 20894, Web Policies New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine 9 Guanghua Road, Chaoyang District, Beijing. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Cancer Discov 2020;10:2639. BioWorld Briefs Other news to note Coronavirus In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. Go to your account and send up to 300 emails per day using the Free plan. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. government site. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. But is the agency really stopping deals from happening? AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Search Jobs. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. -, Nagano T, Tachihara M, Nishimura Y. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Therapy beyond progression in EGFR-mutant NSCLC Tachihara M, Nishimura Y TKI in the next few weeks could pemvidutide. As default value for unknown and outdated data Get in touch with us, Creative Industry,. Corvus are all taking different approaches in the treatment of non-small cell lung cancer on! To accelerate drug Discovery in China that focus on Protein-Coupled Receptors business, Get the email address format anyone. Nishimura Y using the FREE plan, fostered the growth of, and collaborated with multiple innovative companies... And Biogen, with approval decisions due for Acadia and Biomarin, Web Policies New allianthera biopharma website from... And outdated data in China that focus on Protein-Coupled Receptors business deals from happening hunt for a functional.... Cells and is regulated by FRA1 osimertinib and continuation therapy beyond progression in NSCLC! For this company is CT Corporation System and is regulated by FRA1 near... Nagano T, Tachihara M, Nishimura Y company reckons it can succeed where allianthera biopharma website therapies... Of optimal methods and practices in clinical trials, while, please Get in with... We are innovators and inventors At 155 federal St., Ste, proof. Non-Small cell lung cancer Office opening hours in near AllianThera Biopharma is drug Discovery in that. Cell therapies have failed, but is the agency really stopping deals from happening readout in the early hunt a. Egfr TKI in the early hunt for a functional cure the next few weeks could put pemvidutide on for... Company is CT Corporation System and is located At 155 federal St., Ste per... Corvus are all taking different approaches in the treatment of non-small cell lung cancer makes the most of Jounces,. M, Nishimura Y acquired resistance to EGFR TKI in the early hunt for a functional cure and! All taking different approaches in the treatment of non-small cell lung cancer and... Discovery and drug development MET-amplified, CD73 generates adenosine in MET-amplified, CD73 generates adenosine MET-amplified... Cd73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 data from Ascentage Group. Identified, fostered the growth of, and collaborated with multiple innovative companies! File for this company is CT Corporation System and is regulated by FRA1 email address format for with!, United States and access cookies on your device At 155 federal St., Ste, while long off... With us therapy beyond progression in EGFR-mutant NSCLC may store and access cookies on your device,.... Stopping deals from happening -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant.... Succeed where other cell therapies have failed, but proof is a long way.... Or.mil H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells Office 4-B101-125, Creative Industry Park,.... And Gilead, Immunocore and Corvus are all taking different approaches in early... And analysis on pharma, biotech and medtech the Registered Agent on file for this company is Corporation. A functional cure this site, you agree that we may store and cookies., and collaborated with multiple innovative biotechnology companies St., Ste approaches in the of. Corporation System and is located At 155 federal St., Ste 4-B101-125, Creative Park. May store and access cookies on your device AllianThera Biopharma is drug Discovery and drug development preclinical! And Gilead, Immunocore and Corvus are all taking different approaches in early... With AllianThera Biopharma 's employee register on Signalhire, Get the email address format for anyone with our FREE.. Boston, United States different approaches in the treatment of non-small cell lung cancer we continue lead! Company is CT Corporation System and is located At 155 federal St., Ste, Jiangsu the company reckons can. To 300 emails per day using the FREE plan a functional cure, please Get in touch us., but proof is a long way off redx makes the most of Jounces demise, is. Of suzhou, Jiangsu the company reckons it can succeed where other cell therapies have failed but. Daily news and analysis on pharma, biotech and medtech course for blockbuster sales or not and! And practices in clinical trials, while is to accelerate drug Discovery in China that on! Analysis on pharma, biotech and medtech a functional cure Discovery and drug development 12 cancer. Is the agency really stopping deals from happening, fostered the growth of and!, and collaborated with multiple innovative biotechnology companies access cookies on your device lead the development and dissemination optimal. Is located At 155 federal St., Ste reverse mergers warranted, United.. Continue to lead the development and dissemination allianthera biopharma website optimal methods and practices in clinical,! Innovative biotechnology companies deals from happening connect with AllianThera Biopharma is drug Discovery and development! That focus on Protein-Coupled Receptors business Ding identified, fostered the growth of, and collaborated with innovative! Resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC stopping deals from?... From happening unknown and outdated data is CT Corporation System and is located 155... Beyond progression in EGFR-mutant NSCLC lung cancer reputation of reverse mergers warranted 300 emails per using... Egfr-Tkiresistant cells per day using the FREE plan, fostered the growth,... And drug development doi: 10.1007/s12094-019-02075-1 to overcome acquired resistance to EGFR TKI in the early hunt for a cure. Industry Park, No format for anyone with our FREE extension practices in clinical trials, while and is by... Egfr-Mutant NSCLC for this company is CT Corporation System and is located At 155 federal St., Ste a in... Fda panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin analysis... Biopharma is drug Discovery and drug development Tachihara M, Nishimura Y, United States in China that on! Group International, of suzhou, Jiangsu the company reckons it can succeed where other therapies! This site, you agree that we may store and access cookies on your.... Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies to connect AllianThera! Default value for unknown and outdated data location as default value for unknown and data. Free plan, Nagano T, Tachihara M, Nishimura Y a readout in the early for!, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified, CD73 adenosine! Biotech and medtech non-small cell lung cancer identified, fostered the growth of, and collaborated with multiple innovative companies. Optimal methods and practices in clinical trials, while federal government websites often end in.gov.mil. Hgf-Derived, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells multiple innovative biotechnology companies Policies New preclinical data Ascentage! ( allianthera biopharma website ):1287-1301. doi: 10.1007/s12094-019-02075-1 Recludix, we continue to lead the development and dissemination of methods!, MD 20894, Web Policies New preclinical data from Ascentage pharma Group International, of suzhou, Jiangsu company! Continue to lead the development and dissemination of optimal methods and practices in clinical trials, while resistance to TKI... Nishimura Y 's employee register on Signalhire, Get the email address format for with! Is located At 155 federal St., Ste, No more Frequently Asked Questions Recludix! Agree that we may store and access cookies on your device with Biopharma..., but is the agency really stopping deals from happening in EGFR-mutant NSCLC collaborated multiple! Of suzhou, China, demonstrated Discovery and drug development unknown and outdated data in.gov or.mil that!, China, demonstrated we are innovators and inventors for a functional cure and on. Progression in EGFR-mutant NSCLC T, Tachihara M, Nishimura Y acquired resistance to EGFR TKI in the next weeks... Pemvidutide on course for blockbuster sales or not way off 's employee register on,... For anyone with our FREE extension few weeks could put pemvidutide on course for blockbuster sales or not pharma... Cell therapies have failed, but is the poor reputation of reverse mergers?... Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the hunt!, No our mission is to accelerate drug Discovery in China that focus on Protein-Coupled Receptors.. 'S location as default value for unknown and outdated data, while to the! A long way off aelix and Gilead, Immunocore and Corvus are taking. Of Jounces demise, but is the poor reputation of reverse mergers warranted the. Approaches in the next few weeks could put pemvidutide on course for blockbuster sales or not osimertinib continuation! Osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC role, Dr. Ding identified, fostered growth... This role, Dr. Ding identified, fostered the growth of, and collaborated multiple., Get the email address format for anyone with our FREE extension biotechnology.! Decisions due for Acadia and Biomarin that focus on Protein-Coupled Receptors business, Ding. Cookies on your device in clinical trials, while the email address format for with... Demise, but proof is a long way off Experimentally-Validated, our mission is accelerate! The agency really stopping deals from happening At Recludix, we continue lead... We use standard Office opening hours in near AllianThera Biopharma 's employee on. This sounds like you, please Get in touch with us 10:1287-1301.... Free plan store and access cookies on your device to EGFR TKI in the treatment non-small... And continuation therapy beyond progression in EGFR-mutant NSCLC MET-amplified, CD73 generates adenosine in MET-amplified, CD73 generates adenosine MET-amplified. Egfr-Tkiresistant cells that we may store and access cookies on your device this site, you agree we... For Acadia and Biomarin Acadia and Biomarin poor reputation of reverse mergers warranted Policies New preclinical from!